Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($9.23) EPS for the quarter, beating analysts’ consensus estimates of ($444.29) by $435.06, FiscalAI reports. The business had revenue of $2.34 million for the quarter, compared to analyst estimates of $4.85 million.
Jaguar Animal Health Price Performance
Jaguar Animal Health stock opened at $0.39 on Tuesday. The stock has a market capitalization of $756,994.00, a P/E ratio of -0.00 and a beta of -0.09. The company’s fifty day moving average price is $3.92 and its 200 day moving average price is $99.74. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.40 and a current ratio of 0.69. Jaguar Animal Health has a 1 year low of $0.36 and a 1 year high of $981.75.
Analyst Ratings Changes
Several equities analysts recently weighed in on the company. Wall Street Zen upgraded Jaguar Animal Health to a “sell” rating in a research note on Saturday, October 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Jaguar Animal Health presently has an average rating of “Sell”.
View Our Latest Stock Report on Jaguar Animal Health
Jaguar Animal Health Company Profile
Jaguar Health, Inc., formerly Jaguar Animal Health, develops prescription medicines for gastrointestinal disorders in humans and animals. The company’s research has focused on plant-derived compounds, including crofelemer, which is derived from the Croton lechleri tree. Jaguar’s animal-health product Canalevia-CA1 received FDA conditional approval for the treatment of chemotherapy-induced diarrhea in dogs. The company also develops and commercializes crofelemer-based medicines for human gastrointestinal conditions.
Recommended Stories
- Five stocks we like better than Jaguar Animal Health
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
Receive News & Ratings for Jaguar Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
